-
Je něco špatně v tomto záznamu ?
HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications
J. Malikova, T. Zingg, R. Fingerhut, S. Sluka, M. Grössl, S. Brixius-Anderko, R. Bernhardt, J. McDougall, AV. Pandey, CE. Flück,
Jazyk angličtina Země Švýcarsko
Typ dokumentu kazuistiky, časopisecké články
PubMed
31256164
DOI
10.1159/000500522
Knihovny.cz E-zdroje
- MeSH
- benzoxaziny * aplikace a dávkování škodlivé účinky MeSH
- buněčné linie MeSH
- dospělí MeSH
- HIV infekce farmakoterapie MeSH
- infekční komplikace v těhotenství farmakoterapie MeSH
- inhibitory reverzní transkriptasy * aplikace a dávkování škodlivé účinky MeSH
- kongenitální adrenální hyperplazie * chemicky indukované enzymologie MeSH
- lidé MeSH
- novorozenec MeSH
- předčasný porod * chemicky indukované enzymologie MeSH
- steroid-21-hydroxylasa antagonisté a inhibitory metabolismus MeSH
- těhotenství MeSH
- zpožděný efekt prenatální expozice * chemicky indukované enzymologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
BACKGROUND: The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine. OBJECTIVE: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic enzyme activity of CYP21A2 specifically in an in vitro system. METHODS: We tested the effect of efavirenz, tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were treated with the drugs at different concentrations including concentrations in therapeutic use. The effect on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to assess direct drug effects on CYP21A2 activity. RESULTS: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations. Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis. Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. CONCLUSION: The HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis at therapeutic concentrations. This may have clinical implications for HIV treatment in children and adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical conclusions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006200
- 003
- CZ-PrNML
- 005
- 20230712142449.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000500522 $2 doi
- 035 __
- $a (PubMed)31256164
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Křenek Malíková, Jana $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Department of Pediatrics, University Hospital Motol, SecondFaculty of Medicine, Charles University in Prague, Prague, Czechia. $7 xx0158263
- 245 10
- $a HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications / $c J. Malikova, T. Zingg, R. Fingerhut, S. Sluka, M. Grössl, S. Brixius-Anderko, R. Bernhardt, J. McDougall, AV. Pandey, CE. Flück,
- 520 9_
- $a BACKGROUND: The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine. OBJECTIVE: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic enzyme activity of CYP21A2 specifically in an in vitro system. METHODS: We tested the effect of efavirenz, tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were treated with the drugs at different concentrations including concentrations in therapeutic use. The effect on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to assess direct drug effects on CYP21A2 activity. RESULTS: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations. Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis. Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. CONCLUSION: The HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis at therapeutic concentrations. This may have clinical implications for HIV treatment in children and adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical conclusions.
- 650 12
- $a kongenitální adrenální hyperplazie $x chemicky indukované $x enzymologie $7 D000312
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a benzoxaziny $x aplikace a dávkování $x škodlivé účinky $7 D048588
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a infekční komplikace v těhotenství $x farmakoterapie $7 D011251
- 650 12
- $a předčasný porod $x chemicky indukované $x enzymologie $7 D047928
- 650 12
- $a zpožděný efekt prenatální expozice $x chemicky indukované $x enzymologie $7 D011297
- 650 12
- $a inhibitory reverzní transkriptasy $x aplikace a dávkování $x škodlivé účinky $7 D018894
- 650 _2
- $a steroid-21-hydroxylasa $x antagonisté a inhibitory $x metabolismus $7 D013255
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zingg, Tanja $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
- 700 1_
- $a Fingerhut, Ralph $u Swiss Newborn Screening Laboratory, Children's Research Center (CRC), University Children's Hospital of Zurich, Zurich, Switzerland.
- 700 1_
- $a Sluka, Susanna $u Swiss Newborn Screening Laboratory, Children's Research Center (CRC), University Children's Hospital of Zurich, Zurich, Switzerland.
- 700 1_
- $a Grössl, Michael $u Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- 700 1_
- $a Brixius-Anderko, Simone $u Department of Biochemistry, Faculty of Technical and Natural Sciences, Saarland University, Saarbrücken, Germany.
- 700 1_
- $a Bernhardt, Rita $u Department of Biochemistry, Faculty of Technical and Natural Sciences, Saarland University, Saarbrücken, Germany.
- 700 1_
- $a McDougall, Jane $u Division of Neonatology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- 700 1_
- $a Pandey, Amit V $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- 700 1_
- $a Flück, Christa E $u Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, christa.flueck@dbmr.unibe.ch. Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, christa.flueck@dbmr.unibe.ch.
- 773 0_
- $w MED00175757 $t Hormone research in paediatrics $x 1663-2826 $g Roč. 91, č. 4 (2019), s. 262-270
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31256164 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20230712142451 $b ABA008
- 999 __
- $a ok $b bmc $g 1525058 $s 1096256
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 91 $c 4 $d 262-270 $e 20190628 $i 1663-2826 $m Hormone research in paediatrics $n Horm Res Paediatr $x MED00175757
- LZP __
- $a Pubmed-20200511